Article

Extended-release pegaptanib injection under development

Eyetech Inc. has entered into a licensing and development agreement with SurModics Pharmaceuticals Inc. to develop an extended-release version of pegaptanib sodium injection (Macugen) using microparticle technology.

Palm Beach Gardens, FL-Eyetech Inc. has entered into a licensing and development agreement with SurModics Pharmaceuticals Inc. to develop an extended-release version of pegaptanib sodium injection (Macugen) using microparticle technology.

The drug, a selective inhibitor of vascular endothelial growth factor (VEGF)-165, is approved for the treatment of neovascular age-related macular degeneration (AMD). The goal of the extended-release formulation is to decrease the frequency of dosing from every 6 weeks to every 4 to 6 months.

“An extended-release formulation of [pegaptanib sodium injection] could offer several potential advantages to physicians, patients with neovascular AMD, and their families, including a more convenient dosing schedule, improved compliance, and a lower risk of complications related to the injection,” said Scott W. Cousins, MD, project leader for the Macugen Microparticles Program and vice chairman of research in the Department of Ophthalmology at Duke University School of Medicine, Durham, NC.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
© 2025 MJH Life Sciences

All rights reserved.